PE20231651A1 - Compuestos para el tratamiento de enfermedades y trastornos asociados a braf - Google Patents

Compuestos para el tratamiento de enfermedades y trastornos asociados a braf

Info

Publication number
PE20231651A1
PE20231651A1 PE2022002894A PE2022002894A PE20231651A1 PE 20231651 A1 PE20231651 A1 PE 20231651A1 PE 2022002894 A PE2022002894 A PE 2022002894A PE 2022002894 A PE2022002894 A PE 2022002894A PE 20231651 A1 PE20231651 A1 PE 20231651A1
Authority
PE
Peru
Prior art keywords
braf
treatment
diseases
compounds
disorders associated
Prior art date
Application number
PE2022002894A
Other languages
English (en)
Inventor
Tanna Marie Bettendorf
Barbour Patrick Michael Doerner
Dean Russell Kahn
Alex Andrew Kellum
Ellen Ruth Laird
David Austin Moreno
Li Ren
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of PE20231651A1 publication Critical patent/PE20231651A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona en la presente un compuesto de la Formula I: o una sal aceptable desde el punto de vista farmaceutico de este, en donde R1, R2, R3, R4, R5, R6, R7 y L son como se definen en la presente, para el tratamiento de enfermedades y trastornos asociados a BRAF, incluso tumores asociados a BRAF.
PE2022002894A 2020-06-09 2021-06-04 Compuestos para el tratamiento de enfermedades y trastornos asociados a braf PE20231651A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063036522P 2020-06-09 2020-06-09
US202063116204P 2020-11-20 2020-11-20
US202163175655P 2021-04-16 2021-04-16
PCT/IB2021/054919 WO2021250521A1 (en) 2020-06-09 2021-06-04 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders

Publications (1)

Publication Number Publication Date
PE20231651A1 true PE20231651A1 (es) 2023-10-17

Family

ID=76355554

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002894A PE20231651A1 (es) 2020-06-09 2021-06-04 Compuestos para el tratamiento de enfermedades y trastornos asociados a braf

Country Status (18)

Country Link
US (1) US20220288074A1 (es)
EP (1) EP4161907A1 (es)
JP (2) JP7312335B2 (es)
KR (1) KR20230019944A (es)
CN (1) CN116096710A (es)
AU (1) AU2021289163A1 (es)
BR (1) BR112022024597A2 (es)
CA (1) CA3186343A1 (es)
CL (1) CL2022003326A1 (es)
CO (1) CO2022017876A2 (es)
CR (1) CR20220626A (es)
DO (1) DOP2022000282A (es)
EC (1) ECSP22093029A (es)
IL (1) IL298300A (es)
MX (1) MX2022015703A (es)
PE (1) PE20231651A1 (es)
UY (1) UY39261A (es)
WO (1) WO2021250521A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221027A1 (es) * 2019-12-10 2022-06-16 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
WO2023105371A1 (en) * 2021-12-08 2023-06-15 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
WO2023178284A1 (en) * 2022-03-17 2023-09-21 St. Jude Children’S Research Hospital Treatment of low-grade glioma with mirdametinib
WO2023183470A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2130536B1 (en) 2002-03-13 2013-05-08 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
BRPI0416692A (pt) 2003-11-19 2007-01-30 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de emprego destes
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
BRPI0610139A2 (pt) 2005-05-18 2010-06-01 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de uso dos mesmos
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
AU2017204973A1 (en) 2016-01-06 2018-07-12 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as EGFR inhibitors
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
US11661075B2 (en) 2018-09-11 2023-05-30 NetraDyne, Inc. Inward/outward vehicle monitoring for remote reporting and in-cab warning enhancements
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
ECSP22093029A (es) 2023-02-28
JP2023524910A (ja) 2023-06-13
US20220288074A1 (en) 2022-09-15
BR112022024597A2 (pt) 2022-12-27
IL298300A (en) 2023-01-01
JP7312335B2 (ja) 2023-07-20
EP4161907A1 (en) 2023-04-12
KR20230019944A (ko) 2023-02-09
JP2023123854A (ja) 2023-09-05
TW202214577A (zh) 2022-04-16
DOP2022000282A (es) 2023-03-31
MX2022015703A (es) 2023-01-24
CN116096710A (zh) 2023-05-09
WO2021250521A1 (en) 2021-12-16
CA3186343A1 (en) 2021-12-16
UY39261A (es) 2022-01-31
AU2021289163A1 (en) 2022-12-22
CL2022003326A1 (es) 2023-02-24
CO2022017876A2 (es) 2022-12-20
CR20220626A (es) 2023-01-23

Similar Documents

Publication Publication Date Title
PE20231651A1 (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
CO2022008091A2 (es) Inhibidores de kras g12c
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
AR116604A1 (es) Inhibidores de kras g12c
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CY1121231T1 (el) Παραγωγο τετραϋδροϊμιδαζο[1,5-d][1,4]οξαζεπινης
CR20170605A (es) DERIVADOS DE 3-TETRAZOLIL-BENCENO-1,2-DISULFONAMIDA COMO INHIBIDORES DE METALO -ß-LACTAMASA
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
WO2014141110A3 (en) Aminonitriles as kynurenine pathway inhibitors
CO2021017438A2 (es) Derivados de quinazolin-4-ona útiles en el tratamiento de enfermedades y trastornos asociadas con braf
CL2020002157A1 (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
CY1124346T1 (el) ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
MX2021012105A (es) Compuestos de pirrol.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2021008535A2 (es) Compuestos de quinolina como inhibidores de quinasas tam y met
CY1120608T1 (el) Φαρμακευτικως δραστικες ενωσεις
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PH12020551772A1 (en) Oxo-substituted compound
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний